Limits...
Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature.

Moustafa GA, Moschos MM - BMC Ophthalmol (2015)

Bottom Line: RT in the right eye decreased to 129 μm.Multifocal electroretinogram response did not improve, yet peaks were better-shaped and no areas of eccentral vision were present.This first-reported case indicates that intravitreal aflibercept injection for addressing CME in RP seems to be an effective treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Electrophysiology Laboratory, University of Athens, Athens, Greece. giannis.a.moustafa@gmail.com.

ABSTRACT

Background: Cystoid macular edema (CME) in retinitis pigmentosa (RP) has been managed in several ways as documented in the literature, with little success, though. The aim of our study was to report for the first time in literature the use of aflibercept in a patient with RP and CME.

Case presentation: A 52-year-old man presented for blurred vision in his right eye. Best-corrected visual acuity (BCVA) was 3/10 in his right eye and 7/10 in his left eye. Physical examination and appropriate laboratory tests lead to the diagnosis of bilateral RP with CME in the right eye. Retinal thickness in the foveal area of the right eye was 631 μm. The patient was treated with a single intravitreal injection of 0.05 ml/0.5 mg aflibercept. One month later, BCVA of the right eye increased to 4/10, while BCVA of the left eye was unchanged. RT in the right eye decreased to 129 μm. Multifocal electroretinogram response did not improve, yet peaks were better-shaped and no areas of eccentral vision were present. Three and six months after injection, these improvements were maintained.

Conclusion: This first-reported case indicates that intravitreal aflibercept injection for addressing CME in RP seems to be an effective treatment.

Show MeSH

Related in: MedlinePlus

OCT scans of the right eye at presentation (A) and one month after intravitreal aflibercept (B) with macular thickness measuring 631 μm and 129 μm, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4482192&req=5

Fig3: OCT scans of the right eye at presentation (A) and one month after intravitreal aflibercept (B) with macular thickness measuring 631 μm and 129 μm, respectively.

Mentions: A 52-year-old caucasian man (Figure 1) with no remarkable past medical and family history was referred to the First Department of Ophthalmology, University of Athens, Greece complaining for blurred vision in his right eye. Upon examination, BCVA was 7/10 in his left eye and 3/10 in his right eye. Fundoscopy of the left eye revealed mid-peripheral hyperpigmentary spots in form of bone-spicules and arteriolar narrowing, while in the right eye clinical findings were similar (Figure 2). Appropriate visual field tests, OCT and multifocal electroretinogram (mfERG) [25] were performed and, eventually, the patient was diagnosed with RP and CME of the right eye. OCT (Spectralis®, Track Laser Tomography) was performed to evaluate the macular edema. In addition to this, mfERG was performed to assess retinal function. OCT scan showed intraretinal fluid and a significant increase in retinal thickness in the foveal (631 μm) area (Figure 3). Moreover, mfERG showed decreased response in both eyes. The mean P1 retinal response density (RRD) amplitude of the foveal area was 86 nV/deg2 in right eye and 106 nV/deg2 in left eye (Figure 4).Figure 1


Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature.

Moustafa GA, Moschos MM - BMC Ophthalmol (2015)

OCT scans of the right eye at presentation (A) and one month after intravitreal aflibercept (B) with macular thickness measuring 631 μm and 129 μm, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4482192&req=5

Fig3: OCT scans of the right eye at presentation (A) and one month after intravitreal aflibercept (B) with macular thickness measuring 631 μm and 129 μm, respectively.
Mentions: A 52-year-old caucasian man (Figure 1) with no remarkable past medical and family history was referred to the First Department of Ophthalmology, University of Athens, Greece complaining for blurred vision in his right eye. Upon examination, BCVA was 7/10 in his left eye and 3/10 in his right eye. Fundoscopy of the left eye revealed mid-peripheral hyperpigmentary spots in form of bone-spicules and arteriolar narrowing, while in the right eye clinical findings were similar (Figure 2). Appropriate visual field tests, OCT and multifocal electroretinogram (mfERG) [25] were performed and, eventually, the patient was diagnosed with RP and CME of the right eye. OCT (Spectralis®, Track Laser Tomography) was performed to evaluate the macular edema. In addition to this, mfERG was performed to assess retinal function. OCT scan showed intraretinal fluid and a significant increase in retinal thickness in the foveal (631 μm) area (Figure 3). Moreover, mfERG showed decreased response in both eyes. The mean P1 retinal response density (RRD) amplitude of the foveal area was 86 nV/deg2 in right eye and 106 nV/deg2 in left eye (Figure 4).Figure 1

Bottom Line: RT in the right eye decreased to 129 μm.Multifocal electroretinogram response did not improve, yet peaks were better-shaped and no areas of eccentral vision were present.This first-reported case indicates that intravitreal aflibercept injection for addressing CME in RP seems to be an effective treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Electrophysiology Laboratory, University of Athens, Athens, Greece. giannis.a.moustafa@gmail.com.

ABSTRACT

Background: Cystoid macular edema (CME) in retinitis pigmentosa (RP) has been managed in several ways as documented in the literature, with little success, though. The aim of our study was to report for the first time in literature the use of aflibercept in a patient with RP and CME.

Case presentation: A 52-year-old man presented for blurred vision in his right eye. Best-corrected visual acuity (BCVA) was 3/10 in his right eye and 7/10 in his left eye. Physical examination and appropriate laboratory tests lead to the diagnosis of bilateral RP with CME in the right eye. Retinal thickness in the foveal area of the right eye was 631 μm. The patient was treated with a single intravitreal injection of 0.05 ml/0.5 mg aflibercept. One month later, BCVA of the right eye increased to 4/10, while BCVA of the left eye was unchanged. RT in the right eye decreased to 129 μm. Multifocal electroretinogram response did not improve, yet peaks were better-shaped and no areas of eccentral vision were present. Three and six months after injection, these improvements were maintained.

Conclusion: This first-reported case indicates that intravitreal aflibercept injection for addressing CME in RP seems to be an effective treatment.

Show MeSH
Related in: MedlinePlus